Clinical-Risk Factors that Influence an Optimal Hypomethylating Agents Treatment in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. (April 2017) - Iastrebner, M.; Lazzarino, C.; Nucifora, E.; Penchasky, D.; Fernandez, I.; Gusmao Moreno, B.G.M.; Rivas, M.M.; Espinosa, D.; Abello Polo, V.; Boada, M.; Enrico, A.; Araujo Schuster, S.; et al.